Literature DB >> 7011256

Prostacyclin (epoprostenol): its effect on canine splanchnic blood flow during hemorrhagic shock.

R F Seelig, J C Kerr, R W Hobson, G W Machiedo.   

Abstract

Prostacyclin (epoprostenol, prostaglandin I2) is a vasodilator of the splanchnic circulation during normotensive states. To confirm the persistence of its effects after hemorrhagic shock, six anesthetized, previously splenectomized, adult mongrel dogs were subjected to hemorrhagic shock using a modified Wigger's technique in which a mean arterial pressure of 30 mm Hg was maintained until 25% of the shed blood spontaneously returned. The animals were randomly resuscitated with normal saline solution or a similar volume of saline solution containing prostacyclin. Organ blood flow was calculated by measuring the distribution of radioactively tagged microspheres. During shock, blood flows to the liver, small intestine, pancreas, and carcass were reduced. During a 60-minute infusion, prostacyclin selectively caused a significant increase in hepatic arterial blood flow. This improvement in arterial blood flow may prove beneficial in the clinical management of hemorrhagic shock.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7011256     DOI: 10.1001/archsurg.1981.01380160044009

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  3 in total

Review 1.  Drug interactions with thrombolytic agents. Current perspectives.

Authors:  A de Boer; J M van Griensven
Journal:  Clin Pharmacokinet       Date:  1995-04       Impact factor: 6.447

2.  [Significance of therapy timing for the effects of systemic and local therapy with the ACE inhibitor captopril on intestinal microcirculation in manifest mesenteric ischemia. An animal experiment study in the swine].

Authors:  J Jakschik; P Decker; A Hirner
Journal:  Langenbecks Arch Chir       Date:  1995

3.  The effects of prostacyclin on gastric intramucosal pH in patients with septic shock.

Authors:  P Radermacher; R Buhl; B Santak; M Klein; H W Kniemeyer; H Becker; J Tarnow
Journal:  Intensive Care Med       Date:  1995-05       Impact factor: 17.440

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.